The effect of orciprenaline and its p-hydroxyphenyl derivative on the peak expiratory flow rate in asthmatic patients.
D000336:Aerosols; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009921:Metaproterenol / Q000627:therapeutic use; D010919:Placebos; D012118:Resorcinols / Q000627:therapeutic use*; D012119:Respiration / Q000187:drug effects; D013147:Spirometry
D000336:Aerosols; D001993:Bronchodilator Agents; D010919:Placebos; D012118:Resorcinols; D009921:Metaproterenol